| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1037689769 |
| P356 | DOI | 10.1038/NRRHEUM.2014.167 |
| P698 | PubMed publication ID | 25314016 |
| P50 | author | Eamonn S. Molloy | Q111628931 |
| P2093 | author name string | Leonard H Calabrese | |
| Joseph Berger | |||
| P2860 | cites work | Drug-induced PML: a global agenda for a global challenge | Q83540853 |
| The basis for modeling progressive multifocal leukoencephalopathy pathogenesis | Q83885148 | ||
| Therapy: Targeted but not trouble-free: efalizumab and PML | Q84335968 | ||
| Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection | Q24523687 | ||
| Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps | Q26823444 | ||
| The pathogenesis of progressive multifocal leukoencephalopathy | Q26999906 | ||
| Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors | Q28244625 | ||
| Progressive multifocal leukoencephalopathy in a patient treated with natalizumab | Q28255536 | ||
| Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
| Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 | ||
| Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. | Q30354301 | ||
| PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
| Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease | Q31117183 | ||
| Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression | Q33510514 | ||
| Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy | Q34201921 | ||
| Asymptomatic reactivation of JC virus in patients treated with natalizumab | Q34801034 | ||
| Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis | Q36190565 | ||
| JC virus antibody status underestimates infection rates | Q37079703 | ||
| JC viremia in natalizumab-treated patients with multiple sclerosis | Q37167142 | ||
| Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? | Q37242800 | ||
| Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies | Q37331090 | ||
| JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab | Q39012188 | ||
| Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy | Q43115882 | ||
| Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy | Q43474104 | ||
| PML and rheumatology: the contribution of disease and drugs | Q44175332 | ||
| Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases | Q44893878 | ||
| Anti-JC virus antibodies: implications for PML risk stratification | Q45373492 | ||
| The bone marrow, B cells, and JC virus | Q45389810 | ||
| A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. | Q46097425 | ||
| Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation | Q46228478 | ||
| Risk factors for rare diseases can be risky to define: PML and natalizumab | Q46814512 | ||
| Goal-oriented patient care--an alternative health outcomes paradigm | Q48005694 | ||
| Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies | Q60962707 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P304 | page(s) | 119-123 | |
| P577 | publication date | 2014-10-14 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Sorting out the risks in progressive multifocal leukoencephalopathy | |
| P478 | volume | 11 |
| Q98664276 | Adipocyte Plasma Membrane Protein (APMAP) promotes JC Virus (JCPyV) infection in human glial cells |
| Q39161011 | Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy |
| Q38851093 | Advances in the treatment of cutaneous lupus erythematosus |
| Q26799201 | Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis |
| Q37716829 | Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts |
| Q35948285 | Infection and Lupus: Which Causes Which? |
| Q28084300 | Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy? |
| Q40621149 | John cunningham (JC) virus genotypes in kidney transplant recipients, rheumatoid arthritis patients and healthy individuals in Isfahan, Iran |
| Q26783070 | Optimizing therapy early in multiple sclerosis: An evidence-based view |
| Q48938768 | PML risk stratification using anti-JCV antibody index and L-selectin. |
| Q52587612 | Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. |
| Q39325788 | Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases |
| Q38689838 | Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. |
| Q36503933 | Quantitative Proteomic Analysis of Enriched Nuclear Fractions from BK Polyomavirus-Infected Primary Renal Proximal Tubule Epithelial Cells |
| Q90132737 | Simultaneous Development of Progressive Multifocal Leukoencephalopathy and Cryptococcal Meningitis during Methotrexate and Infliximab Treatment |
| Q38665891 | Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions |
| Q38815391 | Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs |
| Q38708002 | Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous |
Search more.